Comparative effectiveness of individual pneumococcal vaccines with dual pneumococcal vaccination in older United States Veterans

Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

(2022) Miwako Kobayashi et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age

(2021) Nicola P. Klein et al.   VACCINE

Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age

(2020) Donald Hurley et al.   CLINICAL INFECTIOUS DISEASES

Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices

(2019) Almea Matanock et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Validation of discharge diagnosis codes to identify serious infections among middle age and older adults

(2018) Andrew D Wiese et al.   BMJ Open

Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2018) Christopher Troeger et al.   LANCET INFECTIOUS DISEASES

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

(2018) James T. Peterson et al.   Human Vaccines & Immunotherapeutics

Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review

(2016) Cornelius Remschmidt et al.   BMC INFECTIOUS DISEASES

Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia

(2016) Naomi J. Gadsby et al.   CLINICAL INFECTIOUS DISEASES

Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults

(2015) Seema Jain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine–naïve adults 60–64 years of age

(2014) Richard N. Greenberg et al.   VACCINE

Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: Results of a one-year study

(2013) Daniel M. Musher et al.   JOURNAL OF INFECTION

Distribution of 13-Valent Pneumococcal Conjugate Vaccine Streptococcus pneumoniae Serotypes in US Adults Aged >=50 Years With Community-Acquired Pneumonia

(2013) R. L. Sherwin et al.   JOURNAL OF INFECTIOUS DISEASES

A Within-Patient Analysis for Time-Varying Risk Factors of CKD Progression

(2013) L. Li et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

(2013) Lisa A. Jackson et al.   VACCINE

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults

(2013) Lisa A. Jackson et al.   VACCINE

Risk of Community-Acquired Pneumonia in Veteran Patients to Whom Proton Pump Inhibitors Were Dispensed

(2011) J. A. Hermos et al.   CLINICAL INFECTIOUS DISEASES

Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines

(2011) Jan Poolman et al.   Expert Review of Vaccines

Safety and Antibody Response, Including Antibody Persistence for 5 Years, after Primary Vaccination or Revaccination with Pneumococcal Polysaccharide Vaccine in Middle‐Aged and Older Adults

(2010) Daniel M. Musher et al.   JOURNAL OF INFECTIOUS DISEASES

Clinical and economic burden of community-acquired pneumonia among adults in Europe

(2010) T Welte et al.   THORAX

Etiology of Community‐Acquired Pneumonia: Increased Microbiological Yield with New Diagnostic Methods

(2009) Niclas Johansson et al.   CLINICAL INFECTIOUS DISEASES

Immortal time bias in critical care research: Application of time-varying Cox regression for observational cohort studies*

(2009) Ayumi K. Shintani et al.   CRITICAL CARE MEDICINE